We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Refine your search

Content type


Firm name


760 results found


Loeb & Loeb LLP | USA | 30 Apr 2019

FDA Regulatory and Compliance Monthly Recap April 2019

The guidance describes what pediatric information should be included in the labeling of drugs and biologics and where it should be located to make it


Riker Danzig Scherer Hyland & Perretti LLP | USA | 8 Apr 2019

Riker Danzig Health Care Update April 8, 2019

New Jersey State: Selected Proposed and Adopted Legislation


Robinson & Cole LLP | USA | 8 Apr 2019

CBD Update: FDA Issues Statement, Calls Public Hearing, and Announces Warning Letters on Products Containing Cannabis and its Components

On April 2, 2019, the Federal Food and Drug Administration (FDA) issued a statement and announced a public hearing on consumer products derived from


Hall Render Killian Heath & Lyman PC | USA | 5 Apr 2019

Hall Render’s This Week in Washington - April 5, 2019

Speaking on the Senate floor on Thursday, Sen. Lamar Alexander (R-TN), Chairman of the Health, Education, Labor, and Pensions (“HELP”) Committee


Haynes and Boone LLP | USA | 29 Mar 2019

It’s All in the Name: Updated FDA Guidance on Nonproprietary Naming of Biologic Products

In January 2017, the FDA published guidance that adopted a naming convention that attaches a distinguishing suffix to the proper names of both


Finnegan, Henderson, Farabow, Garrett & Dunner LLP | USA | 19 Mar 2019

FDA Final Guidance on the Nonproprietary Naming of Biological Products: Update

On March 7, 2019, FDA issued draft guidance that describes FDA’s current thinking on nonproprietary names of biological products licensed under


Rothwell, Figg, Ernst & Manbeck, PC | USA | 17 Mar 2019

Biosimilars Will Get Special Names- Suffixes Are Here to Stay

Announcing that it will create special names for biosimilar products to distinguish them from previously approved biologic products


Baker & Hostetler LLP | USA | 12 Mar 2019

FDA and Pharmacy Weekly Digest - March 12

FDA Commissioner Announces Resignation - Food and Drug Administration Commissioner Scott Gottlieb announced his resignation, citing personal reasons


Riker Danzig Scherer Hyland & Perretti LLP | USA | 11 Mar 2019

Riker Danzig Health Care Update March 11, 2019

New Jersey State: Selected Proposed and Adopted Legislation


Epstein Becker Green | USA | 26 Feb 2019

FDA Finalizes Two Guidance Documents Regarding Regenerative Medicine Therapies

On February 15, 2019, the U.S. Food and Drug Administration (“FDA”) finalized two guidance documents regarding regenerative medicine therapies (see

Previous page 1 2 3 ...